wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 7. no 2. June 2002  
 TABLE OF CONTENT

 Diagnostics and treatment of allergy
Why anti-IgE?
Ewa Cichocka-Jarosz, Ewa Nizankowska-Mogilnicka*

Klinika Chorób Dzieci Katedry Pediatrii Collegium Medicum UJ, ul. Wielicka 265, 30-663 Kraków
*Klinika Pulmonologii II Katedry Chorób Wewnętrznych Collegium Medicum UJ, ul. Skawińska 8, 31-066 Kraków



Atopy – an inherited, genetically determined capacity to produce abnormal amounts of specific IgE – is the basic cause of the so-called atopic diseases – bronchial asthma, allergic rhinitis and allergic conjunctivitis. Immunoglobulin E expresses biological action through specific high affinity (FceRI) and low affinity (FceRII) receptors, presented on the surface of different cells. The regulation of IgE synthesis is controlled by T-lymphocytes. Due to the growing prevalence of atopic diseases, the new methods of causal treatment, apart from traditional ones, are explored. Up till now the only method influencing the immunological patomechanism of atopic diseases was specific immunotherapy. The new alternative may be the humanized murine monoclonal antibody anti-IgE (omalizumab, rhuMAb-E25). The drug binds to free IgE, reduces its level, blocks the binding of IgE to FceRI receptor and downregulates the activation of inflammatory cells. First attempts at applying omalizumab in randomized double blind studies, indicate its efficacy both in adults and children with bronchial asthma or allergic rhinitis. The usefulness of the drug is associated with the improvement of clinical symptoms score, lung function tests and the quality of life, reduction of rescue medication, steroid-sparing effect. The drug is well tolerated, with side-effects similar to those of placebo. This novel promising therapy requires further follow-up monitoring as far as its efficacy and safety are concerned, giving the hope for widening the indications for its application.
Alergia Astma Immunologia, 2002, 8(2), 65-72



keywords: IgE, atopia, omalizumab, rhuMAb-E25, IgE, atopy, omalizumab, rhuMAb-E25

pages: from 65 to 72



estimated time of download (723 kB)
broadband speed:561282565121024[kbps]
time:1464624127[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.